Mebendazole: Hidden Potential and FDA-Approved Hope (2025) - The Wellness Company
Recently, Mel Gibson appeared on The Joe Rogan Experience, where he made a fascinating yet controversial claim — that his friends reportedly overcame cancer using fenbendazole, a veterinary anthelmintic drug. While stories like these spark curiosity, it’s essential to separate anecdotal evidence from established science.
What many people don’t realize is that a closely related drug, mebendazole, is FDA-approved for human use and has been extensively studied for both its antiparasitic and potential anti-cancer effects.
As far back as 2002, Mukhopadhyay and colleagues showed that mebendazole was effective in killing lung cancer cell lines. Currently, mebendazole is in Phase I and Phase II clinical trials for pediatric brain cancers (pediatric gliomas) with trials scheduled for completion in April 2025 (2,3).
Mebendazole was pulled from the U.S. market in 2011 for non-safety-related reasons and later reintroduced in 2016 at an astonishingly inflated price. The cost of a standard three-day treatment skyrocketed from $31.92 to $2,656.80. The reason given for the price surge was its outstanding effectiveness and monopoly by a single pharmaceutical company at the time. (Perhaps the 2002 study on lung cancer had something to do with this (4)?
This is where ivermectin, a Nobel Prize-winning drug, comes into play. Ivermectin enhances mebendazole’s effects by:
Because of this, it has been more extensively tested through ongoing clinical trials
Fenbendazole was found to promote liver tumors in one study.

Ivermectin and Mebendazole are powerful, research-backed treatments with established safety profiles, offering promising potential beyond their traditional uses. We make them available because everyone deserves the ability to make informed health decisions without barriers.
Citations:
What many people don’t realize is that a closely related drug, mebendazole, is FDA-approved for human use and has been extensively studied for both its antiparasitic and potential anti-cancer effects.
Mebendazole: An FDA-Approved Anthelmintic with Ongoing Cancer Research
Mebendazole was first discovered in 1968 and later marketed as an anthelmintic drug, used to treat a range of parasitical worm infections, including tapeworms, roundworms, and threadworms. It is in the same class as albendazole and others1. However, its potential extends beyond parasites.As far back as 2002, Mukhopadhyay and colleagues showed that mebendazole was effective in killing lung cancer cell lines. Currently, mebendazole is in Phase I and Phase II clinical trials for pediatric brain cancers (pediatric gliomas) with trials scheduled for completion in April 2025 (2,3).
Mebendazole was pulled from the U.S. market in 2011 for non-safety-related reasons and later reintroduced in 2016 at an astonishingly inflated price. The cost of a standard three-day treatment skyrocketed from $31.92 to $2,656.80. The reason given for the price surge was its outstanding effectiveness and monopoly by a single pharmaceutical company at the time. (Perhaps the 2002 study on lung cancer had something to do with this (4)?
How Mebendazole and Ivermectin Work Together
Mebendazole’s mechanism of action is twofold:- It disrupts microtubules — the structural framework within cells — by binding to tubulin proteins.
- It impairs glucose uptake, starving parasites of energy.
This is where ivermectin, a Nobel Prize-winning drug, comes into play. Ivermectin enhances mebendazole’s effects by:
- Blocking multiple pathways cancer cells use to survive
- Inhibiting metastasis (the spread of cancer)
- Promoting apoptosis (programmed cell death)
- Reversing drug resistance, making cancer cells more susceptible to treatment (5,6,7)
Why Mebendazole and not Fenbendazole?
Mebendazole is FDA-approved for human use and has an established safety profile in humans.Because of this, it has been more extensively tested through ongoing clinical trials
Fenbendazole was found to promote liver tumors in one study.
Why We Make These Medications Available
We believe in providing access to essential medications that have been overlooked or restricted due to monopolization and pricing manipulation — despite their well-documented benefits.Ivermectin and Mebendazole are powerful, research-backed treatments with established safety profiles, offering promising potential beyond their traditional uses. We make them available because everyone deserves the ability to make informed health decisions without barriers.
Citations:
|
Comments
Post a Comment